MedPath

PFIZER INC.

PFIZER INC. logo
🇺🇸United States
Ownership
Public
Established
1849-01-01
Employees
88K
Market Cap
$163.3B
Website
http://www.pfizer.com

A Study Of Combined C- MET Inhibitor And PAN-HER Inhibitor (PF-02341066 And PF-00299804) In Patients With Non- Small Cell Lung Cancer

Phase 1
Completed
Conditions
Non Small Cell Lung Cancer
Interventions
First Posted Date
2010-05-12
Last Posted Date
2015-10-28
Lead Sponsor
Pfizer
Target Recruit Count
70
Registration Number
NCT01121575
Locations
🇺🇸

Brigham & Women's Hospital, Boston, Massachusetts, United States

🇺🇸

Drug Shipment Only, Boston, Massachusetts, United States

🇺🇸

Clinical Trials Office University of Colorado Hospital (CTO), Aurora, Colorado, United States

and more 6 locations

Study To Assess The Effect Of Gabapentin, Diphenhydramine And Morphine On Cold Pain In Healthy Male Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2010-05-07
Last Posted Date
2011-03-07
Lead Sponsor
Pfizer
Target Recruit Count
19
Registration Number
NCT01119222
Locations
🇧🇪

Pfizer Investigational Site, Bruxelles, Belgium

A Study To Observe The Performance Of A Tablet Form Of PF-04531083 As Evidenced By The Concentration Of PF-04531083 In The Blood With Time Following Oral Administration To Healthy Volunteers.

Phase 1
Completed
Conditions
Chronic Pain
Interventions
First Posted Date
2010-05-07
Last Posted Date
2010-08-06
Lead Sponsor
Pfizer
Target Recruit Count
24
Registration Number
NCT01119235
Locations
🇧🇪

Pfizer Investigational Site, Bruxelles, Belgium

Study To Assess The Reproducibility And Sensitivity Of Quantitative Sensory Testing In Patients With Neuropathic Pain

Not Applicable
Completed
Conditions
Neuropathic Pain
Interventions
Drug: Placebo
First Posted Date
2010-05-05
Last Posted Date
2019-04-23
Lead Sponsor
Pfizer
Target Recruit Count
31
Registration Number
NCT01117766
Locations
🇬🇧

Pfizer Investigational Site, London, United Kingdom

Study In Healthy Adult Volunteers To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of PF-04427429

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2010-05-05
Last Posted Date
2012-01-18
Lead Sponsor
Pfizer
Target Recruit Count
40
Registration Number
NCT01117233
Locations
🇧🇪

Pfizer Investigational Site, Bruxelles, Belgium

Cross Over Convenience And Preference Study Of New Mark VII Compared To Genotropin Pen In Pediatric And Adult Subjects

Phase 3
Completed
Conditions
Growth Hormone Deficiency
Interventions
Device: Genotropin Pen
Device: MARK VII pen
First Posted Date
2010-04-28
Last Posted Date
2012-05-22
Lead Sponsor
Pfizer
Target Recruit Count
120
Registration Number
NCT01112865
Locations
🇸🇪

Barn och Ungdomsmedicinkliniken, Linkoping, Sweden

🇬🇧

Salford Royal NHS Foundation Trust, Hope Hospital, Salford, Manchester, United Kingdom

🇨🇿

Fakultni nemocnice v Motole, Praha 5, Czech Republic

and more 19 locations

Child Pneumococcal Serotype Epidemiology In Greece

Completed
Conditions
Pneumococcal Disease
Interventions
Other: no intervention
First Posted Date
2010-04-27
Last Posted Date
2013-01-10
Lead Sponsor
Pfizer
Target Recruit Count
457
Registration Number
NCT01111214
Locations
🇬🇷

Agia Sophia Children's Hospital, Athens, Attiki, Greece

🇬🇷

University Hospital of Alexandroupolis, Alexandroupoli, Greece

🇬🇷

University Hospital of Herakleion, Herakleion, Greece

and more 6 locations

A Study to Investigate the Effects of PF00610335 on the QT/QTC Interval in Healthy Volunteers

Phase 1
Completed
Conditions
Pulmonary Disease
Lung Disease
Moxifloxacin
Interventions
First Posted Date
2010-04-20
Last Posted Date
2011-01-13
Lead Sponsor
Pfizer
Target Recruit Count
48
Registration Number
NCT01107054
Locations
🇧🇪

Pfizer Investigational Site, Bruxelles, Belgium

A Dose Finding Study Of A New Medication, PF-00337210 That Will Possibly Decrease Blood Supply To Tumors

Phase 1
Completed
Conditions
Neoplasm
Interventions
Drug: PF-00337210
First Posted Date
2010-04-16
Last Posted Date
2013-03-19
Lead Sponsor
Pfizer
Target Recruit Count
46
Registration Number
NCT01105533
Locations
🇺🇸

Pfizer Investigational Site, Madison, Wisconsin, United States

Evaluate Parasitological Clearance Rates And Pharmacokinetics Of The Combination Of Azithromycin And Chloroquine In Asymptomatic Pregnant Women With Falciparum Parasitemia In Africa

Phase 3
Terminated
Conditions
Asymptomatic Parasitemia In Pregnancy
Interventions
First Posted Date
2010-04-15
Last Posted Date
2015-01-26
Lead Sponsor
Pfizer
Target Recruit Count
168
Registration Number
NCT01103713
Locations
🇰🇪

Siaya District Hospital, Siaya, Kenya

🇹🇿

Teule Hospital, Muheza, Tanga, Tanzania

🇧🇯

Centre de Sante d'AHOUANSORI -AGUE, Cotonou, Benin

and more 4 locations
© Copyright 2025. All Rights Reserved by MedPath